Therapeutic Advances in Hematology

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
Therapeutic Advances in Hematology - Tập 9 Số 11 - Trang 335-346 - 2018
Johnny Mahlangu
Whilst the global prevalence of haemophilia B is less than that of haemophilia A, rapid and remarkable innovations have been made in the development of haemophilia B therapies in the last decade. The most recent developments are the evolution of extended half-life haemophilia B replacement therapies which are designed to reduce the treatment burden associated with prophylactic infusion of...... hiện toàn bộ
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Therapeutic Advances in Hematology - Tập 10 - 2019
Guillaume Richard‐Carpentier, Courtney D. DiNardo
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidine and decitabine, which have historically provided only short-lived and modest benefits. Th...... hiện toàn bộ
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Therapeutic Advances in Hematology - Tập 5 Số 3 - Trang 65-77 - 2014
Seth A. Wander, Mark J. Levis, Amir Fathi
Acute myeloid leukemia remains associated with poor outcomes despite advances in our understanding of the complicated molecular events driving leukemogenesis and malignant progression. Those patients harboring mutations in the FLT3 receptor tyrosine kinase have a particularly poor prognosis; however, significant excitement has been generated by the emergence of a variety of targeted inhib...... hiện toàn bộ
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Therapeutic Advances in Hematology - Tập 7 Số 3 - Trang 142-156 - 2016
Jonathan Benjamin, Anthony S. Stein
Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative option for adult patients with relapsed/refractory ALL, and a...... hiện toàn bộ
Tổng số: 4   
  • 1